21 participants
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-07-17
- Start Date:
- 2020-10-01
- Completion:
- 2023-12-01
Conditions
- Adrenocortical Carcinoma
Interventions
- DRUG
No Results Yet